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I M M U N O L O G Y
Chimeric camel/human heavy-chain antibodies protect 
against MERS-CoV infection
V. Stalin Raj1*†‡, Nisreen M. A. Okba1*, Javier Gutierrez-Alvarez2, Dubravka Drabek3, 
Brenda van Dieren4, W. Widagdo1, Mart M. Lamers1, Ivy Widjaja4, Raul Fernandez-Delgado2, 
Isabel Sola2, Albert Bensaid5, Marion P. Koopmans1, Joaquim Segalés6,7, 
Albert D. M. E. Osterhaus8,9, Berend Jan Bosch4, Luis Enjuanes2, Bart L. Haagmans1‡
Middle East respiratory syndrome coronavirus (MERS-CoV) continues to cause outbreaks in humans as a result of 
spillover events from dromedaries. In contrast to humans, MERS-CoV–exposed dromedaries develop only very 
mild infections and exceptionally potent virus-neutralizing antibody responses. These strong antibody responses 
may be caused by affinity maturation as a result of repeated exposure to the virus or by the fact that dromedaries— 
apart from conventional antibodies—have relatively unique, heavy chain–only antibodies (HCAbs). These HCAbs 
are devoid of light chains and have long complementarity-determining regions with unique epitope binding 
properties, allowing them to recognize and bind with high affinity to epitopes not recognized by conventional 
antibodies. Through direct cloning and expression of the variable heavy chains (VHHs) of HCAbs from the bone 
marrow of MERS-CoV–infected dromedaries, we identified several MERS-CoV–specific VHHs or nanobodies. In vitro, 
these VHHs efficiently blocked virus entry at picomolar concentrations. The selected VHHs bind with exceptionally 
high affinity to the receptor binding domain of the viral spike protein. Furthermore, camel/human chimeric 
HCAbs—composed of the camel VHH linked to a human Fc domain lacking the CH1 exon—had an extended half-life 
in the serum and protected mice against a lethal MERS-CoV challenge. HCAbs represent a promising alternative 
strategy to develop novel interventions not only for MERS-CoV but also for other emerging pathogens.
INTRODUCTION
In 2012, a novel virus, termed Middle East respiratory syndrome 
coronavirus (MERS-CoV), was identified in humans (1). Six years 
later, more than 2000 laboratory-confirmed MERS cases, including 
36% with a fatal outcome, have been reported globally. Most cases thus 
far originated from the Arabian Peninsula, as a result of hospital 
outbreaks (2). There is convincing evidence that dromedary camels 
are the primary source of MERS-CoV infection in humans. The virus 
isolated from camels is similar to that isolated from humans and also 
replicates in human cells (3). In addition, epidemiological and phylo-
genetic analyses suggest multiple introductions of MERS-CoV into the 
human population (2, 4). This raises a great concern as MERS-CoV 
could continue to cause outbreaks in the near future. Effective prophy-
lactic and therapeutic intervention strategies are therefore needed to 
combat this virus.
Monoclonal antibodies (mAbs) are promising candidates for the 
treatment and prevention of viral infections. Recently, MERS-CoV– 
neutralizing mAbs have been identified and characterized by several 
research groups, using various approaches. These antibodies have 
been isolated from human naïve B cells (5), memory B cells of MERS- 
CoV–infected individuals (6), or transgenic mice expressing human 
antibody variable heavy chains (VHHs) and  light chains (7). All these 
mAbs target the receptor binding domain (RBD) of the MERS-CoV 
spike protein. The MERS-CoV spike protein is a structural viral com-
ponent that contains the RBD, located in the S1 subunit of the protein, 
which binds to the MERS-CoV entry receptor dipeptidyl peptidase-4 
(DPP4) (8). Antibodies raised against the S1 or RBD block MERS-CoV 
infection in vitro (9, 10), and the most potent mAbs identified against 
MERS-CoV thus far recognize the RBD (5, 7, 11–14). However, pro-
duction of these mAbs at a large scale is costly and requires a long 
developmental process, and relative large quantities might be needed 
to protect humans against a viral infection (15). Alternatively, anti-
body engineering technologies allow the cloning of variable regions 
of mAbs for expression in Escherichia coli or yeast to produce large 
amounts of recombinant antibody fragments (16). To date, 68 thera-
peutic mAbs have been licensed, of which 7 are chimeric antibodies (17).
Heavy chain–only antibodies (HCAbs) are naturally produced in 
camelid species (18). These antibodies are dimeric and do not con-
tain a light chain, and their antigen recognition region is solely formed 
by the VHH region termed single-domain antibody fragment. This 
fragment is about 14 kDa in size, is relatively stable, and can be pro-
duced with high yields in prokaryotic systems (18, 19). Camelid 
VHHs have long complementarity-determining region 3 (CDR3) 
loops, capable of binding to unique epitopes not accessible to con-
ventional antibodies (20). Because of these beneficial properties, 
VHHs have been exploited for a range of biotechnological applica-
tions, including diagnostics, therapeutics, and fundamental research 
(21, 22). The recent preclinical success of a VHH that blocks von 
Willebrand factor–mediated platelet aggregation (23) shows their 
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therapeutic potential. VHHs may also efficiently prevent entry of 
viruses into host cells (24). Chimeric HCAbs, which have the camel 
VHH and the human Fc portion (lacking the CH1 exon as in camel 
HCAbs), allow them to interact with human effector cells and com-
plement cascade factors (15).
Several studies have demonstrated the presence of high levels of 
MERS-CoV–specific neutralizing antibodies (mean virus neutral-
ization titer ≈ 1000) in dromedary camels in the Middle East and 
Africa (25–27). Therefore, next to human mAbs, characterization of 
MERS-CoV–neutralizing VHHs from dromedary camels could serve 
as an alternative strategy to develop neutralizing antibodies. Here, we 
report the identification and characterization of neutralizing VHHs 
against MERS-CoV from immunized dromedary camels and demon-
strate the prophylactic activity of camel/human chimeric HCAbs in 
a MERS-CoV transgenic mouse model.
RESULTS
Identification of MERS-CoV–specific VHHs from a dromedary 
camel bone marrow complementary DNA library
First, we identified MERS-CoV–neutralizing VHHs by direct cloning 
and screening of VHH complementary DNA (cDNA) libraries 
derived from bone marrow cells (given the high frequency of specific 
plasma cells) rather than using B cells from peripheral blood of 
immunized animals (Fig. 1). Bone marrow was obtained from two 
dromedary camels immunized with modified vaccinia virus encoding 
the MERS-CoV spike protein and subsequently challenged with live 
MERS- CoV (28). At the time of sampling, MERS-CoV–neutralizing 
antibodies were detected at very high levels (titer > 10,000) in the sera 
of these dromedaries (Fig. 2A). Subsequently, VHH-specific primers 
(29) were used to amplify a VHH library from the bone marrow 
cDNA by nested polymerase chain reaction (PCR) (fig. S1, A to C). 
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Fig. 1. Schematic overview of VHH identification by direct cloning using bone marrow from immunized dromedary camels. Immunized dromedary camels were 
anesthetized, and bone marrow aspirations were performed. After total RNA isolation and first-strand cDNA synthesis, VHH genes were amplified and cloned into a pro-
karyotic expression vector (pMES4) and transformed into E. coli WK6. Individual clones were grown overnight in 96-deep-well plates, during which they expressed the 
VHHs in the periplasm. Next, crude VHHs were released from the periplasm by freeze-thawing the bacterial pellet. Crude VHHs were used for immunofluorescent staining 
on virus-infected cells. Immunofluorescent positive clones were further characterized for their genetic makeup, specificity, and potency by sequencing, antigen-specific 
enzyme-linked immunosorbent assay (ELISA), virus neutralization assay, epitope mapping, and structural analysis. Finally, potent VHHs were produced as camel/human 
chimeric single chain–only antibodies.
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After gel purification, PCR products were directly cloned into 
the dephospho rylated prokaryotic expression vector pMES4, tag-
ging the VHHs with six histidine amino acids at the C terminus 
(29). To obtain a high- diversity repertoire of VHHs, we reduced 
the number of amplification cycles. The ligated VHH plasmid 
library was transformed into E. coli strain WK6 and plated on 
ampicillin nutrient agar plates without preculturing the bacteria 
in nutrient medium. A total of 560 VHH clones (225 from camel 1 
and 335 from camel 2) were obtained in a single transformation 
event, and grown individually in 96-deep-well plates. Periplasmic 
expression of recombinant VHHs was induced by isopropyl- -
d-thiogalactopyranoside (Fig. 1). VHHs were purified from the 
periplasm as a crude extract (30), and expression was verified 
using SDS–polyacrylamide gel electrophoresis (PAGE) analysis 
(fig. S1D).
Next, we used formalin-fixed and permeabilized virus-infected cells 
[either MERS-CoV–infected or severe acute respiratory syndrome 
coronavirus (SARS-CoV)–infected] to select for MERS-CoV–specific 
VHHs using immunofluorescent staining. Crude periplasmic VHH 
extracts were incubated on the infected cells, and VHH cell binding 
was visualized with a fluorescently labeled anti-histidine antibody as a 
secondary antibody. All 560 VHH clones were screened by confocal 
microscopy (Fig. 2B). We obtained 204 MERS-CoV–reactive VHHs 
(41.7% from camel 1 and 58.3% from camel 2), of which none reacted 
to SARS-CoV–infected cells. To confirm the specificity of the VHHs 
for MERS-CoV, we randomly selected several clones for double stain-
ing of MERS-CoV–infected cells using a rabbit anti–MERS-CoV serum, 
revealing that these VHHs exclusively targeted MERS-CoV–infected 
cells (Fig. 2C).
Blocking of RBD binding to receptor DPP4 by MERS-CoV 
spike-specific VHHs in vitro
To test whether the VHHs identified in our study recognized the 
RBD or other parts of the S1, we performed MERS-CoV S1– and 
MERS-CoV RBD–specific ELISAs. Out of 204 MERS-CoV–reactive 
VHHs, 188 (92.15%) were directed against the MERS-CoV S1 
subunit, of which 46 VHHs (22.5%) blocked the binding of recom-
binant S1 to the MERS-CoV receptor present on Huh-7 cells 
(fig. S2). All these in vitro blocking VHHs were directed against 
the RBD (Fig. 2D).
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Fig. 2. Identification of VHHs directed against the spike (S) protein of MERS-CoV. (A) Virus-neutralizing antibody titers (VNT) of sera from two dromedary camels 
immunized with MVA expressing the MERS-CoV-S (MVA-S) and challenged with MERS-CoV. (B) Immunofluorescent staining of MERS-CoV–infected Huh-7 cells with crude 
VHHs. Each square represents staining of an individual VHH. (C) Immunofluorescent staining of MERS-CoV–infected Huh-7 cells with rabbit serum (anti–MERS-CoV) or 
crude VHHs and overlay. (D) Correlation of the S1-specific ELISA and the RBD-specific ELISA for the 46 MERS-CoV–neutralizing VHHs (red dots) and control VHHs indicated 
as blue dots (Spearman correlation r = 0.9258; P < 0.0001; 95% confidence interval, 0.8677 to 0.9589). OD, optical density.
 o
n
 N
ovem
ber 15, 2018
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Stalin Raj et al., Sci. Adv. 2018; 4 : eaas9667     8 August 2018
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
4 of 10
Next, we selected all blocking VHHs for further characterization. 
The VHH clone p2E6 (negative for immunofluorescent staining 
and S1 ELISA) was used as the negative control. Using a MERS-CoV 
plaque reduction neutralization test (PRNT), we estimated the 
virus neutralization capacity for each VHH. Except for the control 
VHH-p2E6, all tested VHHs inhibited MERS-CoV entry at varying 
concentrations ranging from 100 to 900 pM (PRNT90; table S1). 
VHHs with high neutralizing capacity (VHH-1, VHH-4, VHH-83, 
and VHH-101) were selected for further characterization.
We obtained sequences from all 46 blocking VHHs. Because 
CDR3 is known to be of most importance for the interaction with 
the antigen, the assumption was made that VHHs with the identi-
cal CDR3 would recognize the same epitope. Overall, 33 VHHs 
had different CDR3 sequences ranging in length from 16 to 20 
amino acids (fig. S3). Phylogenetic analysis of these sequences re-
vealed considerable diversity among the different VHH clones and 
showed that the selected VHHs formed 14 different clusters with 
different CDR3 sequences (fig. S4). All sequences contained the 
characteristic VHH tetrad, except clone 10 that, at amino acid 
positions 37, 45, and 47, shows VH characteristics (valine, leucine, 
and tryptophan). The best MERS-CoV–neutralizing VHHs (VHH-1, 
VHH-4, VHH-83, and VHH-101) had different CDR3 sequences 
(fig. S4).
VHHs bind to MERS-CoV spike protein with high affinity
Subsequently, the best four neutralizing VHHs and the control VHH-
p2E6 were selected for large-scale production and purification. We 
obtained high quantities (5 to 30 mg) of pure (>95%) His-tag affinity- 
purified VHHs from 1 liter of bacterial culture (fig. S5A). Mixing these 
VHHs with recombinant MERS-CoV spike S1 protein generated VHH- 
spike complexes, as observed by nonreducing PAGE analysis (fig. S5B). 
In addition, the equilibrium dissociation constant (Kd) between the 
VHH and spike protein of these four VHHs was relatively low, with 
Kd values ranging from 1 to 0.1 nM, indicating high-affinity binding 
(fig. S6, A and B).
Neutralization of MERS-CoV by VHHs and camel/human 
chimeric HCAbs
Next, we tested the neutralizing activities of these VHHs in vitro by 
PRNT. All four VHHs were confirmed to neutralize MERS-CoV with 
high efficiency, with PRNT50 values ranging from 0.0014 to 0.012 g/ml 
(93 to 800 pM), while no inhibition was observed using the control 
VHH-p2E6 at high concentration (>1.0 g/ml; 67 M; Fig. 3A). Be-
cause of their small size, VHHs are rapidly cleared from the circula-
tion (30, 31). Therefore, we additionally produced the four VHHs as 
camel/human chimeric HCAbs by C-terminal tagging the VHHs with 
the Fc part of human immunoglobulin G2 (IgG2) (containing the hinge 
and CH2 and CH3 exons) (Fig. 1, right). These HCAbs (HCAb-1, 
HCAb-4, HCAb-83, and HCAb-101) form homodimers of about 78 kDa 
in size and exhibit approximately the same neutralizing capacity as 
the monomeric VHHs in vitro (Fig. 3B). Moreover, using an S1-specific 
ELISA, we could detect HCAb binding at even lower concentrations, 
down to 0.00019 g/ml (2.5 pM; Fig. 3C).
Epitope mapping of four potent MERS-CoV–neutralizing VHHs
To map the VHH binding epitopes, we first tested the binding of the 
four different VHHs to recombinant S1 protein using ForteBio’s Octet 
system. As shown in fig. S7, all four VHHs competed for a single 
epitope. Subsequently, we used a set of recombinant S1 proteins that 
contain single amino acid mutations present in spike proteins of 
MERS-CoV field isolates, located within the receptor binding sub-
domain (residues 483 to 566) of the RBD that engages DPP4. MERS-
CoV polyclonal antibodies, an irrelevant VHH, and four VHHs were 
then tested for their ability to bind to these S1 variants. MERS-CoV 
polyclonal antibodies, but not the control VHH-p2E6, bound to all 
variants (Fig. 4, A and B), whereas the four MERS-CoV–specific VHHs 
did not bind to the D539N variant and differed in their binding to 
the other variants. VHH-1 also did not bind to variant E536K, whereas 
VHH-4 and VHH- 101 showed partial binding to three additional 
variants (I529T, V534A, and E536K) (Fig. 4, C to F). These data show 
that all four VHHs bind an epitope in the receptor binding subdomain 
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Fig. 3. MERS-CoV–neutralizing efficacy of monomeric VHHs and chimeric antibodies on Huh-7 cells. MERS-CoV (EMC isolate) was incubated with either VHHs 
(monomer), chimeric antibodies, or controls at various concentrations for 1 hour and then the mix was transferred on Huh-7 cells. Cells were fixed 8 hours after infection 
and stained using rabbit polyclonal antibodies. The PRNT titer was calculated on the basis of a 50% or greater reduction of infected cells (PRNT50). (A) PRNT assay for VHH 
monomer. (B) PRNT for camel/human chimeric heavy-chain antibodies. Experiments were performed at least two times in triplicate, data from an experiment were pre-
sented, and error bars show SEM. (C) MERS-CoV S1 ELISA using different HCAbs. The optical density at 450 nm was presented in triplicate, with error bars showing SEM.
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that is partially overlapping, consistent with the binding competition 
analysis (fig. S7). The RBD residues D537, D539, Y540, and R542 are 
important for the virus to bind to its cellular receptor DPP4 (32, 33). 
Because all four VHHs did not bind to the D539N variant, this sug-
gests that these VHHs neutralize MERS-CoV most likely by blocking 
its binding to its cellular receptor. Despite several attempts, we were 
not able to identify MERS-CoV escape variants in vitro. Because of 
the best neutralizing capacity and epitope recognition, we selected 
VHH-83 and HCAb-83 for further in vivo testing.
In vivo efficacy of VHH-83 and HCAb-83
To test the prophylactic efficacy of VHH-83 or HCAb-83 in vivo, we 
used the K18 transgenic mouse model (34). In our first experiment, 
mice were given VHH-83 or an irrelevant VHH control (p2E6) at 20 
or 200 g per mouse (nine mice per group) by intraperitoneal injec-
tion 6 hours before intranasal infection with a lethal dose of MERS-
CoV (EMC isolate). Mice that received VHH-83 lost weight and died 
within 7 days post-inoculation (dpi), as well as those injected with the 
control VHH (fig. S8).
Next, we tested HCAb-83 or the control HCAb-p2E6 using a sim-
ilar experimental setup. Mice treated with 200 g of HCAb-83 gained 
weight (Fig. 5A), and all mice survived (Fig. 5B). In contrast, control 
HCAb-p2E6–treated groups lost weight and died within 7 dpi (Fig. 5, 
A and B). Gross pathological changes (Fig. 5C), mononuclear cell in-
filtration, and alveolar edema (Fig. 5E) were observed in the lungs of 
control HCAb-p2E6–treated mice on day 4 after inoculation. Whereas 
low doses (20 g) of HCAb-83–treated mice were only partially pro-
tected on the basis of the observed reduction of pathological abnor-
malities on 4 dpi (Fig. 5F), the lungs of high-dose HCAb-83–treated 
mice showed no pathological changes at any time point tested (Fig. 5G). 
In addition, no infectious virus could be isolated from the lungs of 
these mice, while high viral titers were observed in the low dose– and 
control HCAb–treated mice (Fig. 5H).
Pharmacokinetics of HCAb-83
We also evaluated the pharmacokinetics of VHH and HCAb in the 
sera of mice treated with either VHH-83 or HCAb-83. First, we 
estimated the presence of MERS-CoV–neutralizing activity in sera 
obtained 2 days after treatment. No neutralization of the virus was 
observed in the sera of VHH-83– or control VHH-p2E6–treated 
mice (Fig. 6A), consistent with the reported rapid clearance of small 
VHH domains from the circulation (31). Significant levels of 
neutralizing antibodies (mean titer, 1024) were observed in the sera 
of mice treated with 200 g of HCAb-83 and, to a limited extent, in 
low dose–treated mice (mean titer, 64; Fig. 6A). Second, we tested 
the presence of circulating HCAb-83 in the sera obtained at various 
time points after injection (0, 2, 4, and 8 days after treatment) by 
ELISA. As shown in Fig. 6B, 200 g of HCAb-83–treated mice 
still had high levels of HCAb-83 8 days after treatment, with an 
apparent serum half-life of approximately 4.5 days.
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Fig. 4. Effect of MERS-CoV RBD residue substitution on VHH binding. Binding efficiency of VHHs to the wild-type and mutant forms of viral spike glycoprotein was 
analyzed by ELISA. The binding efficiency was calculated on the basis of optical density (OD450) of mutant protein versus that of the wild-type spike. (A) Anti-human IgG 
polyclonal antibodies were used to corroborate equivalent coating of the S1-hFc variants. (B) One irrelevant VHH (VHH-p2E6) lacked binding to wild-type and mutant 
proteins. (C) VHH-1. (D) VHH-4. (E) VHH-83. (F) VHH-101.
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DISCUSSION
VHHs are small in size; have high stability, solubility, and affinity; and 
efficiently recognize antigens. They have many potential biomedical 
applications including the treatment of cancer, autoimmune diseases, 
and virus infections (18, 19, 22, 24, 31). Moreover, VHHs are gain-
ing much attention in the field of diagnostics and therapeutics for 
viral diseases. They have been used for the detection of viruses, such 
as Marburg virus, human immunodeficiency virus (HIV), influenza 
virus, dengue virus, and norovirus (22, 24). VHHs also block virus 
attachment to the host cells in respiratory syncytial virus, influenza 
virus, hepatitis B virus, rotavirus, and HIV infections (22, 24). Some 
VHHs inhibit viral RNA transcription or nuclear import of viral ribo-
nucleoproteins (35). Here, we have shown that MERS-CoV–neutralizing 
VHHs can be obtained from immunized dromedary camels that were 
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challenged with MERS-CoV. The engineered camel/human chimeric 
HCAbs were highly stable in mice, and prophylactically treated mice were 
fully protected from MERS-CoV infection upon challenge with live virus.
Naturally infected dromedary camels have remarkably high levels 
of neutralizing antibodies against MERS-CoV (25, 36). We used drom-
edaries that showed high levels of neutralizing antibodies in their sera 
and identified MERS-CoV–neutralizing VHHs by direct cloning from 
a VHH cDNA library using bone marrow, a major source of highly 
enriched long-lived antibody-producing plasma cells. After immuni-
zation, antigen-stimulated B cells undergo affinity maturation in ger-
minal centers of secondary lymphoid organs, where they differentiate 
into plasma cells that secrete antibodies. Significant portion of long-
lived plasma cells migrate to the bone marrow. A small portion of plas-
ma cells reside in the lymphoid organs, but these are often short-lived 
(37, 38). In mice, 8 days after boost immunization with ovalbumin, 
about 10 to 20% of the antigen-specific plasma cells migrate from sec-
ondary lymphoid organs to the bone marrow (39). In particular, bone 
marrow plasma cells are long-lived and are thus suitable for maintain-
ing antibody levels in the serum for an extended period, which plays a 
significant role in pathogen neutralization and humoral immune re-
sponses (40). The number of S1-specific clones found in the VHH li-
brary generated from vaccinated and infected camels (188 of 560 clones; 
33.5%) was much higher compared to nonvaccinated infected camels 
(12 of 496 clones; 2.4%), suggesting that the vaccination and challenge 
protocol used in this study had a major impact on the frequency of 
S1-specific B cells detected in the bone marrow.
Camelid species have naturally occurring HCAbs. These antibodies 
contain long CDR3 sequences (20), which allow them to interact with 
unique and even recessed epitopes that may not be recognized by con-
ventional antibodies (20, 41). We identified 46 MERS-CoV–neutralizing 
VHHs, of which 4 bound to the RBD of the spike protein with high 
affinity and neutralized MERS-CoV infection at picomolar concentra-
tions. VHH-83 showed a neutralizing capacity down to a concentra-
tion of 30 pM (PRNT50), making it more potent than the most potent 
mAbs described thus far (7, 42). However, direct comparisons between 
different antibodies would require determining the exact differences in 
vitro. Competition and spike protein binding assays showed that the 
four VHHs competed for binding to an overlapping epitope on the 
RBD, which partially overlaps with the RBD-DPP4 interface. Binding 
assays using variant recombinant spike proteins revealed that all four 
VHHs bound to wild-type spike protein but not to a D539N-mutant 
protein. Amino acids E536, D537, and D539 are negatively charged 
residues on the surface of the RBD, which interact with three positively 
charged residues on the outer surface of the DPP4 (32, 33). This indi-
cates that the four VHHs can prevent virus attachment and entry. Given 
the critical role of these amino acids in the DPP4-virus interaction, viral 
escape mutants without loss of fitness are less likely to develop (32, 33). 
This could be the reason why we did not identify HCAb-83 escape 
variants in vitro. However, further (structural) studies are needed to 
pinpoint all RBD-VHH contact residues involved.
Next, we produced the four VHHs as HCAbs, which showed three-
fold enhanced MERS-CoV–neutralizing capacity in comparison to the 
monomeric VHHs in vitro (PRNT50, 30 pM). In contrast to VHH-83, 
mice prophylactically treated with 200 g of HCAb-83 were fully pro-
tected from weight loss and death upon challenge with live virus. No 
infectious virus was detected in the lungs of these mice, and protection 
correlated with the presence of sustained high levels of HCAbs-83 in 
the sera of mice. In addition, most in vivo studies testing mAbs to 
MERS-CoV showed only reduced MERS-CoV replication (two to four 
log reductions in lung virus titer) or complete protection only at higher 
doses used (1000 g per mouse) (6, 7, 13). The high level of neutraliz-
ing activity of HCAb-83 (PRNT50, 30 pM) could be due to the different 
antigen recognition pattern of camelid HCAbs. Recent studies also 
revealed the importance of long CDR3 sequences from bovine anti-
bodies raised against HIV in cross-neutralization against different viral 
serotypes (43). The therapeutic efficacy of HCAb-83 still needs further 
evaluation, but given the limited therapeutic efficacy of other mAbs 
against acute respiratory infections such as respiratory syncytial virus 
in humans (44), prophylactic administration of antibodies may also be 
preferred to contain outbreaks of MERS-CoV.
Apart from direct neutralization, antibodies may also play a role 
in mediating effector functions such as complement-dependent cy-
totoxicity and antibody-dependent cell-mediated cytotoxicity (16). 
HCAb-83 has an Fc domain of human IgG2, which has limited effector 
function in vivo (17), suggesting that the observed protection in mice 
could be mainly due to the neutralizing activity. Therefore, additional 
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studies need to evaluate whether the potency of HCAb-83 may be in-
creased further by replacing the IgG2 Fc with the IgG1 Fc or by com-
bination with other antibodies targeting different epitopes.
In summary, we identified and characterized potent HCAbs that 
neutralized MERS-CoV in vitro and in vivo. Because of their high 
affinity, in vivo stability, and efficacy, these HCAbs may be used as 
a prophylaxis for MERS-CoV.
MATERIALS AND METHODS
Immunization
One female (6-month-old) and one male (8-month-old) healthy 
dromedary camels (Camelus dromedarius), negative for antibodies 
against MERS-CoV and modified vaccinia virus Ankara (MVA), were 
obtained from the Canary Islands and housed in biosecurity level 3 
(BSL-3) facilities [Centre de Recerca en Sanitat Animal (CReSA)], 
as described previously (28). Experimental procedures were approved 
by the local Ethics Committee of the Autonomous University of 
Barcelona (number 8003). Both animals were immunized twice with 
a 4-week interval with 108 plaque-forming units of MVA-S via both 
nostrils and intramuscularly in the neck of the animals. After the second 
immunization, both animals were anesthetized with midazolam 
(5 mg/ml) and inoculated with 107 TCID50 MERS-CoV in 3 ml of 
phosphate-buffered saline (PBS) intranasally in both nostrils using 
a laryngo-tracheal mucosal atomization device (45). Blood samples 
were taken at different dpi. On day 14 after inoculation, both animals 
were anesthetized and femoral bone marrow samples (about 1 cm3) 
were collected next to the epiphysis and placed, each, in tubes con-
taining 3.6 ml of ice-cold fetal calf serum. Specimens were gently 
crushed with a 1-ml tip and homoge nized by slow up and down 
pipetting. After 10-min incubation on ice, 400 l of dimethyl sulf-
oxide was mixed into each tube, and the preparation was dispensed 
into 2-ml cryovials discarding debris and slurs and stored at −135°C.
Protein expression
The recombinant S1-Fc fusion proteins were produced as described 
previously (46). Briefly, plasmids encoding MERS-CoV S1-Fc or 
MERS-CoV RBD-Fc were generated by ligating a fragment encod-
ing the S1 subunit (GenBank accession number AFS88936; residues 
1 to 747) or RBD (residues 358 to 588) 3′ terminally to a fragment 
encoding the Fc domain of human IgG1 into the pCAGGS expression 
vector. Plasmids encoding S1-Fc variants with single amino acid sub-
stitutions were generated by site-directed mutagenesis. S1-Fc fusion 
proteins were expressed by transfection of the expression plasmids 
into human embryonic kidney (HEK)–293T (CRL-11268, American 
Type Culture Collection) cells and affinity-purified from the culture 
supernatant using Protein A-Sepharose beads (GE Healthcare).
Estimation of antibody/VHH titers
MERS-CoV–specific antibody titers were measured by ELISA. First, 
96-well plates were coated with MERS-CoV S1 or MERS-CoV RBD 
proteins at 1 g/ml in PBS (pH 7.4) and incubated overnight at 4°C. 
Wells were then washed three times with PBS, blocked with 10% 
normal goat serum in PBS, and incubated at 37°C for 30 min. Drom-
edary camel sera or VHHs were serially diluted in PBS, 100 l was 
added per well, and plates were incubated at 37°C for 1 hour. Next, 
plates were washed three times in PBS containing 0.05% Tween 20 
(PBST), after which they were incubated with biotin-conjugated goat 
anti-llama antibodies (1:2000, Abcore) or mouse anti-histidine anti-
bodies (1:2000, Thermo Fisher Scientific) at 37°C for 1 hour. After 
three washes with PBST, plates were incubated with streptavidin 
horseradish peroxidase (HRP; 1:10,000, Dako) or goat anti-mouse 
HRP (1:2000, Dako) at 37°C for 1 hour. After this incubation, plates 
were washed three times in PBST and incubated at room temperature 
for 10 min in the presence of 3,3′,5,5′-tetramethylbenzidine substrate 
(eBioscience). Reactions were stopped with 2N H2SO4 (Sigma). The 
absorbance of each sample was read at 450 nm with an ELISA reader 
(Tecan Infinite F200).
RNA isolation and cDNA synthesis
For RNA isolation, cryopreserved bone marrow cells were removed 
from the −135°C freezer and transferred to a 37°C water bath. The 
thawed cell suspension was quickly transferred to 40 ml of ice-cold 
RPMI 1640 (Lonza) medium. Cells were counted, and 107 cells were 
transferred to a new ribonuclease (RNase)–free falcon tube and cen-
trifuged at room temperature at 300g for 10 min. The supernatant 
was completely removed, and cells were subsequently lysed with 1 ml 
of TRIzol reagent (Life Technologies) and 0.2 ml of RNase-free 
chloroform (Life Technologies). The mixture was vortexed for 15 s 
and incubated for 3 min at room temperature, followed by centrifu-
gation at 13,000 rpm for 15 min at 4°C. The aqueous phase was 
transferred to a new tube. Subsequently, RNA was isolated using the 
RNeasy MinElute Cleanup Kit (Qiagen) according to the manufac-
turer’s protocol. Total RNA was quantified at 260 nm using the 
NanoDrop 2000, and the quality of the isolated RNA sample was deter-
mined by measuring the A260/A280 ratio. cDNA was synthesized from 
1.5 g of total RNA using a First-Strand cDNA Synthesis kit (Life 
Technologies). For a 20-l reaction mix, 10 l of RNA, 1 l of deoxy-
nucleoside triphosphate (dNTPs; 10 mM each), 1 l of random hex-
amers (10 mM; Promega), and 1.5 l of distilled water (dH2O) were 
added to a microvial. The mixture was incubated at 65°C for 10 min 
and then at 4°C for 2 min. Next, 6.5 l of reverse transcriptase mix 
containing 4 l of 5× SuperScript III reaction buffer, 1 l of dithio-
threitol (100 mM), 0.5 l of RNase inhibitor (20 U/l), and 1 l of 
SuperScript III reverse transcriptase (200 U/l; Life Technologies) 
were added to the microvial and incubated at 25°C for 5 min, 50°C 
for 45 min, and 70°C for 20 min. cDNA was stored at 4°C until PCR 
amplification.
PCR amplification and cloning of VHH
The amplification of VHH was performed using a nested PCR 
approach (29) that was adapted for use with a high-fidelity DNA 
polymerase (PfuUltra II Fusion HS DNA Polymerase, Stratagene). 
The first PCR mix (50 l of reaction volume) consisted of 5.0 l of 
10× PfuUltra II Fusion HS DNA polymerase buffer, 2.5 l of dNTPs 
(10 mM each), 1.5 l of gene-specific forward primer (CALL001, 
5′-GTCCTGGCTGCTCTTCTACAAGG-3′; 10 mM), 1.5 l of gene- 
specific reverse primer (CALL002, 5′-GGTACGTGCTGTTGAACT-
GTTCC-3′; 10 mM), 1.0 l of PfuUltra II Fusion HS DNA polymerase, 
36.5 l of dH2O, and 2.0 l of cDNA. PCR amplification was per-
formed in a thermocycler with the following protocol: initial dena-
turation at 94°C for 3 min, followed by 20 cycles at 94°C for 20 s, 
50°C for 30 s, and 72°C for 2 min, and a final extension at 72°C for 
10 min. The first PCR generated two amplified products: the heavy 
chain of conventional antibodies (~1000 bp) and the VHH heavy chain 
(~700 bp; fig. S1). The amplified VHH amplicon (~700 bp) was pu-
rified from the agarose gel using the QIAquick Gel Extraction Kit 
(Qiagen), according to the manufacturer’s instructions. The product 
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was then subjected to the second round of PCR amplification using 
VHH inner primers that contained restriction sites for cloning: for-
ward, 5′- CTAGTGCGGCCGCTGGAGACGGTGACCTGGGT-3′ 
(Eco 91I); reverse, 5′-GATGTGCAGCTGCAGGAGTCTGGRG-
GAGG-3′ (Pst I). PCR amplification continued for 12 to 14 cycles, 
after which the amplicons were purified with the QIAquick PCR 
Purification Kit (Qiagen) and digested using Eco 91I and Pst I. The 
vector pMES4 (GenBank accession number GQ907248) was digested 
with the same enzymes and dephosphorylated using alkaline phos-
phatase (New England Biolabs). VHH amplicons were ligated into 
pMES4 using a ratio of 100 ng of vector to 46 ng of VHH (~1:3 molar 
ratio). Next, we used E. coli strain WK6, prepared using the Mix & 
Go! E. coli Transformation Kit and Buffer Set (Zymo Research), for 
transformation according to the manufacturer’s instructions. After 
transformation, cells were directly plated onto an ampicillin (100 g/ml) 
nutrient agar plates. The following day, the insertion of VHH into 
the vector was confirmed by randomly picking 25 clones, screening 
by PCR for the insert, and Sanger sequencing, as described below.
Sequencing
To sequence the inserts, colony PCR was performed using PfuUltra 
II Fusion HS DNA Polymerase (Agilent Technologies) and primers 
(29) 5′-TTATGCTTCCGGCTCGTATG-3′ (MP57) and 5′-CCA-
CAGACAGCCCTCATAG-3′ (GIII) under the following conditions: 
initial denaturation at 95°C for 3 min, followed by 39 cycles of (95°C 
for 20 s, 55°C for 30 s, and 72°C for 40 s), and a final extension at 
72°C for 5 min. The amplicons were gel-purified and sequenced in 
both directions using the BigDye Terminator v3.1 Cycle Sequencing 
Kit and an ABI PRISM 3100 genetic analyzer (Applied Biosystems). 
The obtained sequences were assembled and aligned using CLC 
Genomics Workbench (CLC Bio 4.9).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/4/8/eaas9667/DC1
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Fig. S1. Direct cloning and expression of VHHs.
Fig. S2. VHHs block the interaction between the S1 protein and the MERS-CoV entry receptor 
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Fig. S3. Amino acid sequences of VHH regions of anti–MERS-CoV spike VHHs.
Fig. S4. Phylogenetic tree of the amino acid sequences of the 46 MERS-CoV–neutralizing VHHs 
showing the corresponding neutralizing capacity of each VHH.
Fig. S5. Interaction of selected VHHs with recombinant MERS-CoV spike protein.
Fig. S6. Kinetics of VHH-1, VHH-4, VHH-83, and VHH-101 binding to MERS-CoV spike protein.
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